59 [56]. (Amended) A method according to Claim 58 [55], in which the target cell is a phagocytic cell.

60 [57]. (Amended) A method according to Claim 55 or Claim 59 [56], in which the nucleic acid and hyaluronic acid are administered together *in vitro*.

61 [58]. (Amended) A method according to Claim 58 or Claim 59 [55 or Claim 56], in which the nucleic acid and hyaluronic acid are administered together *in vivo*.

REMARKS

Applicants also are enclosing with this response a substitute copy of the US patent application incorporating the amendments made by the applicant during the PCT phase, in accordance with the PCT Responses filed along with the US application.

A Sequence Listing section is also being provided, in paper and computer readable form, and a Declaration attesting to the best of applicant's agent's knowledge of the correspondence of the originally filed and the sequences included herewith.

The amendments to the specification and the Sequence Listing section added herewith, are fully supported by the specification as filed, by the original claims, the text of the examples, and the Responses filed during the PCT phase of the corresponding Australian patent application. No objectionable new matter is believed to have been introduced by this Amendment.

Applicants are also enclosing a copy of a request for correction of filing date, which, in accordance with the Communication received, has not yet been corrected. The examiner is hereby requested to attain the correction of the filing date.

In view of the foregoing amendments and remarks, this application is believed to be in condition to enter the national phase. Applicants request early notice to this respect.

Respectfully submitted.
ARTER & HADDEN LLP

10/22/99
Date

Viviana Amzel, Ph. D.
Registration No. 30,930
Attorney for Applicant

725 South Figueroa Street
Suite 3400
Los Angeles, California 90017
(213) 430-3520 Ph.
(213) 617-9255 Fax

This correspondence and all attachments mentioned are being deposited in the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC. 20231 on October 22, 1999, by Mary Helen Lopez.

SIGNATURE
h:\Griffith Hack\010\Res w/ Seq Listing.doc
368444.1